Clinical utility of serum S100 in the therapy monitoring of patients with high risk malignant melanoma.

被引：0

作者：

Molina, R. ^{[1
]}

Auge, J. M. ^{[1
]}

Domingo, J. ^{[1
]}

Puig, S. ^{[1
]}

Filella, X. ^{[1
]}

Malvehy, J. ^{[1
]}

Castel, T. ^{[1
]}

机构：

[1] T Castel Biochem & Genet Hosp Clin, IDIBAPS, Barcelona, Spain

来源：

TUMOR BIOLOGY | 2006年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 50 条

[31] Inhibitors of S100B (SBiXs) in malignant melanoma. [J].

Cavalier, Michael ;

Wilder, Paul T. ;

Coop, Andrew ;

MacKerell, Alexander ;

Weber, David J. .

MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)

[32] Expression and clinical significance of S100 family genes in patients with melanoma [J].

Xiong, Ting-feng ;

Pan, Fu-qiang ;

Li, Dong .

MELANOMA RESEARCH, 2019, 29 (01) :23-29

[33] Applicability of reference values for the determination of serum S100 protein as a marker of malignant melanoma in children [J].

Hunzelmann, N ;

Kurschat, P ;

Hani, N ;

Jarisch, A ;

Mauch, C .

BRITISH JOURNAL OF DERMATOLOGY, 2002, 146 (03) :536-537

[34] Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients [J].

Sanmamed, Miguel F. ;

Fernandez-Landazuri, Sara ;

Rodriguez, Carmen ;

Lozano, Maria D. ;

Echeveste, Jose I. ;

Perez Gracia, Jose Luis ;

Alegre, Estibaliz ;

Carranza, Omar ;

Zubiri, Leyre ;

Martin-Algarra, Salvador ;

Gonzalez, Alvaro .

CLINICA CHIMICA ACTA, 2014, 429 :168-174

[35] DETERMINATION OF BIOLOGICAL VARIATION OF S100 IN DISEASE-FREE PATIENTS WITH MALIGNANT MELANOMA [J].

Trape, J. ;

Montesinos, J. ;

Franquesa, J. ;

Sala, M. ;

Figols, C. ;

Miguel, A. ;

Domenech, M. .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 :S279-S279

[36] CLINICAL-SIGNIFICANCE OF SERUM S100 IN METASTATIC MALIGNANT-MELANOMA (VOL 31A, PG 924, 1995) [J].

GUO, HB ;

STOFFELWAGNER, B ;

BIERWIRTH, T ;

MEZGER, J ;

KLINGMULLER, D .

EUROPEAN JOURNAL OF CANCER, 1995, 31A (11) :1898-1902

[37] Comparison of the serum tumor markers S100 and melanoma inhibitory activity (MIA) in the monitoring of melanoma patients undergoing dendritic cell vaccination [J].

Schliep, S. ;

Schliep, K. ;

Erdmann, M. ;

Koch, H. ;

Schuler, G. ;

Schuler-Thurner, B. .

EXPERIMENTAL DERMATOLOGY, 2010, 19 (02) :221-221

[38] New sensitive chemiluminiscence immunoassays for S-100B and the prognostic value of serum S-100 protein in malignant melanoma. [J].

Hansson, LO ;

Djuren, E ;

vonSchoultz, E ;

DijlaiMerzog, R ;

Nilsson, B ;

Hansson, J .

CLINICAL CHEMISTRY, 1997, 43 :574-574

[39] S100 as Serum Tumor Marker in Advanced Uveal Melanoma [J].

Salzmann, Martin ;

Enk, Alexander H. ;

Hassel, Jessica C. .

BIOMOLECULES, 2023, 13 (03)

[40] Fear of progression in patients with low-risk malignant melanoma. [J].

Kaehler, Katharina C. ;

Wagner, Tobias ;

Blame, Christine ;

Forschner, Andrea ;

Garbe, Claus ;

Gutzmer, Ralf ;

Hauschild, Axel ;

Heinzerling, Lucie ;

Livingstone, Elisabeth ;

Lang, Berenice M. ;

Loquai, Carmen ;

Schadendorf, Dirk ;

Terheyden, Patrick ;

Augustin, Matthias .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →